Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $30,043.98 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) EVP Patrick Burnett sold 943 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $31.86, for a total transaction of $30,043.98. Following the completion of the transaction, the executive vice president owned 116,649 shares in the company, valued at $3,716,437.14. This represents a 0.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Wednesday, August 12th, Patrick Burnett sold 6,700 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $26.08, for a total value of $174,736.00.
• On Tuesday, August 11th, Patrick Burnett sold 8,300 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $26.52, for a total transaction of $220,116.00.

Arcutis Biotherapeutics Trading Down 5.4%

Shares of Arcutis Biotherapeutics stock opened at $25.55 on Friday. Arcutis Biotherapeutics, Inc. has a 52-week low of $19.30 and a 52-week high of $34.80. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.67. The firm has a market capitalization of $3.21 billion, a PE ratio of 121.67 and a beta of 1.66. The company’s fifty day moving average price is $27.16 and its two-hundred day moving average price is $25.37.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. The business had revenue of $143.92 million for the quarter, compared to the consensus estimate of $142.59 million. On average, analysts expect that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. TD Cowen raised their price target on Arcutis Biotherapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Cantor Fitzgerald began coverage on shares of Arcutis Biotherapeutics in a research report on Thursday, October 15th. They set an “overweight” rating and a $48.00 target price for the company. Needham & Company LLC set a $40.00 price objective on Arcutis Biotherapeutics in a research report on Thursday. Wall Street Zen cut Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Morgan Stanley raised their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its position in shares of Arcutis Biotherapeutics by 32.7% during the first quarter. Bank of America Corp DE now owns 2,221,289 shares of the company’s stock worth $52,334,000 after buying an additional 547,835 shares during the period. Tejara Capital Ltd purchased a new stake in shares of Arcutis Biotherapeutics in the second quarter worth $2,965,000. Kornitzer Capital Management Inc. KS increased its holdings in Arcutis Biotherapeutics by 55.1% during the first quarter. Kornitzer Capital Management Inc. KS now owns 175,870 shares of the company’s stock valued at $4,143,000 after buying an additional 62,485 shares during the last quarter. Sei Investments Co. boosted its stake in Arcutis Biotherapeutics by 97.7% during the first quarter. Sei Investments Co. now owns 206,141 shares of the company’s stock valued at $4,857,000 after buying an additional 101,855 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in Arcutis Biotherapeutics during the second quarter valued at approximately $2,643,000.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.